{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:33:52Z","timestamp":1790692432349,"version":"4.1.0"},"reference-count":46,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T00:00:00Z","timestamp":1668902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: About 30% of new non-small cell lung cancer (NSCLC) cases are diagnosed at a locally advanced stage, which includes a highly heterogeneous group of patients with a wide spectrum of treatment options. The management of stage III NSCLC involves a multidisciplinary team, adequate staging, and a careful patient selection for surgery or radiation therapy integrated with systemic treatment. Methods: This is a single-center observational retrospective and prospective study including a consecutive series of stage III NSCLC patients who were referred to the Veneto Institute of Oncology and University Hospital of Padova (Italy) between 2012 and 2021. We described clinico-pathological characteristics, therapeutic pathways, and treatment responses in terms of radiological response in the entire study population and in terms of pathological response in patients who underwent surgery after induction therapy. Furthermore, we analysed survival outcomes in terms of relapse-free survival (RFS) and overall survival (OS). Results: A total of 301 patients were included. The majority of patients received surgical multimodality treatment (n = 223, 74.1%), while the remaining patients (n = 78, 25.9%) underwent definitive CRT followed or not by durvalumab as consolidation therapy. At data cut-off, 188 patients (62.5%) relapsed and the median RFS (mRFS) of the entire population was 18.2 months (95% CI: 15.83\u201320.57). At the time of analyses 140 patients (46.5%) were alive and the median OS (mOS) was 44.7 months (95% CI: 38.4\u201351.0). A statistically significant difference both in mRFS (p = 0.002) and in mOS (p &lt; 0.001) was observed according to the therapeutic pathway in the entire population, and selecting patients treated after 2018, a significant difference in mRFS (p = 0.006) and mOS (p &lt; 0.001) was observed according to treatment modality. Furthermore, considering only patients diagnosed with stage IIIB-C (N = 131, 43.5%), there were significant differences both in mRFS (p = 0.047) and in mOS (p = 0.022) as per the treatment algorithm. The mRFS of the unresectable population was 16.3 months (95% CI: 11.48\u201321.12), with a significant difference among subgroups (p = 0.030) in favour of patients who underwent the PACIFIC-regimen; while the mOS was 46.5 months (95% CI: 26.46\u201366.65), with a significant difference between two subgroups (p = 0.003) in favour of consolidation immunotherapy. Conclusions: Our work provides insights into the management and the survival outcomes of stage III NSCLC over about 10 years. We found that the choice of radical treatment impacts on outcome, thus suggesting the importance of appropriate staging at diagnosis, patient selection, and of the multidisciplinary approach in the decision-making process. Our results confirmed that the PACIFIC trial and the following introduction of durvalumab as consolidation treatment may be considered as a turning point for several improvements in the diagnostic-therapeutic pathway of stage III NSCLC patients.<\/jats:p>","DOI":"10.3390\/cancers14225700","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T04:13:36Z","timestamp":1669004016000},"page":"5700","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-3765","authenticated-orcid":false,"given":"Alessandra","family":"Ferro","sequence":"first","affiliation":[{"name":"Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-5587","authenticated-orcid":false,"given":"Matteo","family":"Sepulcri","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schiavon","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Unit, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Scagliori","sequence":"additional","affiliation":[{"name":"Oncologic Radiology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Mancin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5792-4683","authenticated-orcid":false,"given":"Francesca","family":"Lunardi","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisella","family":"Gennaro","sequence":"additional","affiliation":[{"name":"Breast Radiology Unit, Veneto Institute of Oncology-IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Frega","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-717X","authenticated-orcid":false,"given":"Alessandro","family":"Dal Maso","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonanno","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Paronetto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Caumo","sequence":"additional","affiliation":[{"name":"Oncologic Radiology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rea","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Unit, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2022, October 01). Lung and Bronchus Cancer\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The Integration of Radiotherapy with Immunotherapy for the Treatment of Non\u2013Small Cell Lung Cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The Eighth Edition Lung Cancer Stage Classification","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1120","DOI":"10.1200\/OP.20.00899","article-title":"Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey","volume":"17","author":"Salgia","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4329\/wjr.v9.i6.269","article-title":"Revisions to the Tumor, Node, Metastasis Staging of Lung Cancer (8th Edition): Rationale, Radiologic Findings and Clinical Implications","volume":"9","author":"Kay","year":"2017","journal-title":"World J. Radiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines","volume":"19","author":"Ettinger","year":"2021","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and Locally Advanced Non-Small-Cell Lung Cancer: An Update of the ESMO Clinical Practice Guidelines Focusing on Diagnosis, Staging, Systemic and Local Therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2007.14.7371","article-title":"Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non-Small-Cell Lung Cancer: CALGB 30105","volume":"26","author":"Socinski","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1200\/JCO.2002.03.054","article-title":"Randomized Phase II Study of Cisplatin with Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431","volume":"20","author":"Vokes","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13014-019-1239-7","article-title":"Comparative Efficacy and Safety for Different Chemotherapy Regimens Used Concurrently with Thoracic Radiation for Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis","volume":"14","author":"Liu","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.2009.24.7577","article-title":"Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy with Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy with Concurrent Thoracic Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: OLCSG 0007","volume":"28","author":"Segawa","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1200\/JCO.2009.24.5050","article-title":"Phase III Study Comparing Second- and Third-Generation Regimens with Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/1097-0142(19800601)45:11<2744::AID-CNCR2820451108>3.0.CO;2-U","article-title":"A Prospective Randomized Study of Various Irradiation Doses and Fractionation Schedules in the Treatment of Inoperable Non-oat-cell Carcinoma of the Lung. Preliminary Report by the Radiation Therapy Oncology Group","volume":"45","author":"Perez","year":"1980","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-Analysis of Concomitant versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer","volume":"28","author":"Rolland","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"200224","DOI":"10.1183\/16000617.0224-2020","article-title":"Developments in Radiation Techniques for Thoracic Malignancies","volume":"30","author":"Finazzi","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ijrobp.2020.11.040","article-title":"Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study","volume":"109","author":"Haslett","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP Guidelines for Target Volume Definition in the Treatment of Locally Advanced Non-Small Cell Lung Cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-Dose versus High-Dose Conformal Radiotherapy with Concurrent and Consolidation Carboplatin plus Paclitaxel with or without Cetuximab for Patients with Stage IIIA or IIIB Non-Small-Cell Lung Cancer (RTOG 0617): A Randomised, Two-by-Two Factorial P","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial","volume":"35","author":"Chun","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-Term Results of NRG Oncology RTOG 0617: Standard-versus High-Dose Chemoradiotherapy with or without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with Durvalumab by Tumour PD-L1 Expression in Unresectable, Stage III Non-Small-Cell Lung Cancer in the PACIFIC Trial","volume":"31","author":"Spira","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1378\/chest.120.5.1584","article-title":"Grading of Tumor Regression in Non-Small Cell Lung Cancer: Morphology and Prognosis","volume":"120","author":"Junker","year":"2001","journal-title":"Chest"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer after Neoadjuvant Chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological Response after Neoadjuvant Chemotherapy in Resectable Non-Small-Cell Lung Cancers: Proposal for the Use of Major Pathological Response as a Surrogate Endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jtho.2018.11.017","article-title":"Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma","volume":"14","author":"Qu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","unstructured":"Girard, N., Bar, J., Garrido, P., Garassino, M.C., McDonald, F., Mornex, F., Filippi, A.R., Smit, H.J.M., Peters, S., and Field, J.K. (2022). Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. J. Thorac. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jtho.2022.07.016","article-title":"OA01.04 Persisting Gaps in Optimal Care of Stage III Non-Small Cell Lung Cancer: An Australian Patterns of Care Analysis","volume":"17","author":"Woodford","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100508","DOI":"10.1016\/j.ctarc.2021.100508","article-title":"Survival of Clinical Stage III NSCLC According to Therapeutic Strategy: Relevance of the Tumor Board Decision in the Era of Immunotherapy","volume":"30","author":"Benet","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_37","first-page":"100195","article-title":"The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis","volume":"2","author":"Ronden","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative Radiotherapy versus No Postoperative Radiotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer and Proven Mediastinal N2 Involvement (Lung ART): An Open-Label, Randomised, Phase 3 Trial","volume":"23","author":"Pourel","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of Postoperative Radiotherapy for Patients with PIIIA-N2 Non-Small Cell Lung Cancer after Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial","volume":"7","author":"Hui","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41379-021-00777-y","article-title":"A Prognostic Score for Non-Small Cell Lung Cancer Resected after Neoadjuvant Therapy in Comparison with the Tumor-Node-Metastases Classification and Major Pathological Response","volume":"34","author":"Zens","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1078-0432.CCR-19-2379","article-title":"Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade","volume":"26","author":"Stein","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant Atezolizumab and Chemotherapy in Patients with Resectable Non-Small-Cell Lung Cancer: An Open-Label, Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer: State of the Art and Novel Therapeutic Approaches","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2022.02.015","article-title":"Who Benefits from Consolidation Durvalumab in Stage III Non-Small Cell Lung Cancer?","volume":"167","author":"Remon","year":"2022","journal-title":"Eur. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/22\/5700\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:22:30Z","timestamp":1760145750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/22\/5700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,20]]},"references-count":46,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cancers14225700"],"URL":"https:\/\/doi.org\/10.3390\/cancers14225700","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,20]]}}}